Stringent complete response (sCR) in patients (pts) with newly diagnosed multiple myeloma (NDMM) treated with carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (DEX).

被引：0
|
作者：
Jakubowiak, Andrzej J.
Griffith, Kent A.
Dytfeld, Dominik
Vesole, David H.
Jagannath, Sundar
Anderson, Tara B.
Nordgren, Brian K.
Detweiler-Short, Kristen
Lebovic, Daniel
Stockerl-Goldstein, Keith
Jobkar, Terri L.
Wear, Sandra Marija
Al-Zoubi, Ammar
Ahmed, Asra Z.
Mietzel, Melissa A.
Couriel, Daniel R.
Kaminski, Mark Stefan
Hussein, Mohamad A.
Yeganegi, Homa
Vij, Ravi
机构：
[1] Univ Chicago, Chicago, IL 60637 USA
[2] Univ Michigan, Ann Arbor, MI 48109 USA
[3] Poznan Univ Med Sci, Poznan, Poland
[4] Hackensack Univ, Med Ctr, Hackensack, NJ USA
[5] Mt Sinai Med Ctr, New York, NY 10029 USA
[6] Washington Univ, St Louis, MO USA
[7] Multiple Myeloma Res Consortium, Norwalk, CT USA
[8] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA
[9] Univ Michigan Hosp, Ann Arbor, MI 48109 USA
[10] Celgene Corp, Summit, NJ USA
[11] Onyx Pharmaceut, San Francisco, CA USA
[12] Washington Univ, Sch Med, St Louis, MO USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8011
引用
收藏
页数：1
相关论文
共 50 条
  • [1] EXTENDED TREATMENT WITH THE COMBINATION OF CARFILZOMIB (CFZ), LENALIDOMIDE (LEN), AND DEXAMETHASONE ( DEX) IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM)
    Jakubowiak, A.
    Griffith, K.
    Dytfeld, D.
    Vesole, D.
    Jagannath, S.
    Anderson, T.
    Nordgren, B.
    Detweiler-Short, K.
    Lebovic, D.
    Stockerl-Goldstein, K.
    Jobkar, T.
    Wear, S.
    Al-Zoubi, A.
    Ahmed, A.
    Mietzel, M.
    Couriel, D.
    Kaminski, M.
    Hussein, M.
    Yeganegi, H.
    Vij, R.
    HAEMATOLOGICA, 2012, 97 : 115 - 115
  • [2] A randomized, multicenter, phase (Ph) III study comparing carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (Dex) to LEN and Dex in patients (Pts) with relapsed multiple myeloma (MM).
    Moreau, P.
    Palumbo, A. P.
    Stewart, A. K.
    Rajkumar, V.
    Jakubowiak, A. J.
    Halka, K.
    Goranov, S.
    Bumbea, H.
    Pendergrass, K. B.
    Lupu, A.
    Dimopoulos, A.
    Rocafiguera, A. O.
    Gandhi, J. G.
    Mihaylov, G.
    Masszi, T.
    Matous, J.
    Fonseca, G.
    Bryce, R.
    Siegel, D. S. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [3] Phase II MMRC trial of extended treatment with carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (DEX) plus autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (NDMM).
    Zimmerman, Todd M.
    Griffith, Kent A.
    Jasielec, Jagoda
    Rosenbaum, Cara Ann
    McDonnell, Kathryn
    Waite-Marin, Jessica
    Berdeja, Jesus G.
    Raje, Noopur S.
    Reece, Donna Ellen
    Vij, Ravi
    Alonge, Mattina
    Rosebeck, Shaun
    Gurbuxani, Sandeep
    Faham, Malek
    Kong, Katherine A.
    Levy, Joan
    Jakubowiak, Andrzej J.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [4] A phase 1/2 study of durvalumab (DURVA) in combination with lenalidomide (LEN) with or without dexamethasone (DEX) in patients (pts) with newly diagnosed multiple myeloma (NDMM).
    Lonial, Sagar
    Oriol, Albert
    Mateos, Maria-Victoria
    Rodriguez-Otero, Paula
    Bahlis, Nizar J.
    Bensinger, William
    Porkka, Kimmo
    Van De Donk, Niels
    Yiu, Wai
    Di Casoli, Carl
    Ervin-Haynes, Annette L.
    Zaki, Mohamed H.
    Vangsted, Annette
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [5] Sustained Minimal Residual Disease Negativity in Newly Diagnosed Multiple Myeloma (NDMM) Patients Treated with Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (DEX) Followed By 2 Years of Lenalidomide Maintenance (CRd-R): Updated Results of a Phase 2 Study
    Kazandjian, Dickran
    Korde, Neha S.
    Roschewski, Mark
    Mailankody, Sham
    Morrison, Candis
    Manasanch, Elisabet E.
    Kwok, Mary L.
    Tageja, Nishant
    Bhutani, Manisha
    Zingone, Adriana
    Costello, Rene
    Zhang, Yong
    Mulquin, Marcia
    Lamping, Liz
    Carpenter, Ashley
    Roberson, Brenda
    Maric, Irina
    Calvo, Katherine R.
    Braylan, Raul C.
    Yuan, Constance M.
    Stetler-Stevenson, Maryalice
    Arthur, Diane C.
    Lindenberg, Liza
    Kurdziel, Karen A.
    Choyke, Peter
    Steinberg, Seth M.
    Figg, William
    Wilson, Wyndham H.
    Landgren, Ola
    BLOOD, 2016, 128 (22)
  • [6] MICRORNA (MIRNA) EXPRESSION PROFILING IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) TREATED WITH CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (CRD)
    Jasielec, J. K.
    Chen, J. L.
    Rosebeck, S.
    Dytfeld, D.
    Griffith, K.
    Alonge, M.
    McDonnell, K.
    Mietzel, M.
    Couriel, D.
    Kaminski, M.
    Jakubowiak, A.
    HAEMATOLOGICA, 2014, 99 : 366 - 366
  • [7] IMPROVED EFFICACY AFTER INCORPORATING AUTOLOGOUS STEM CELL TRANSPLANT (ASCT) INTO KRD TREATMENT WITH CARFILZOMIB (CFZ), LENALIDOMIDE (LEN), AND DEXAMETHASONE (DEX) IN NEWLY DIAGNOSED MULTIPLE MYELOMA
    Jakubowiak, A.
    Raje, N.
    Vij, R.
    Reece, D.
    Berdeja, J.
    Vesole, D.
    Jagannath, S.
    Cole, C.
    Faham, M.
    Nam, J.
    Stephens, L.
    Severson, E.
    Revethis, A.
    Wolfe, B.
    Rosebeck, S.
    Gurbuxani, S.
    Rosenbaum, C.
    Jasielec, J.
    Dytfeld, D.
    Griffith, K.
    Zimmerman, T.
    HAEMATOLOGICA, 2016, 101 : 1 - 2
  • [8] Carfilzomib (CFZ, Kyprolis®), Lenalidomide (LEN, Revlimide®), and Dexamethasone (DEX) (KRd) Combined with Autologous Stem Cell Transplant (ASCT) Shows Improved Efficacy Compared with Krd without ASCT in Newly Diagnosed Multiple Myeloma (NDMM)
    Zimmerman, Todd M.
    Griffith, Kent
    Jasielec, Jagoda K.
    Rosenbaum, Cara A.
    Berdeja, Jesus G.
    Vij, Ravi
    Raje, Noopur
    Reece, Donna E.
    Vesole, David H.
    Jagannath, Sundar
    Kaminski, Mark
    Cole, Craig
    Nam, Jennifer
    Stephens, Leonor A.
    Rosebeck, Shaun
    Gurbuxani, Sandeep
    Dytfeld, Dominik
    Jakubowiak, Andrzej J.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (03) : S40 - S40
  • [9] Prognostic and Predictive Gene Expression Profiling (GEP) Markers Confirmed in Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Treated Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts)
    van Vliet, Martin
    Jasielec, Jagoda
    Dytfeld, Dominik
    Vij, Ravi
    Dumee, Belinda
    Bosman, Lizanne
    deBest, Leonie C. M.
    Alonge, Mattina
    Rosebeck, Shaun
    Kandarpa, Malathi
    McDonnell, Kathryn
    Griffith, Kent A.
    van Beers, Erik H.
    Jakubowiak, Andrzej
    BLOOD, 2014, 124 (21)
  • [10] Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
    Jakubowiak, Andrzej
    Usmani, Saad Z.
    Krishnan, Amrita
    Lonial, Sagar
    Comenzo, Raymond L.
    Wang, Jianping
    de Boer, Carla
    Deraedt, William
    Weiss, Brendan M.
    Schecter, Jordan M.
    Chari, Ajai
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (10): : 701 - 710
12345